Covid-19: "AstraZeneca" and Oxford University clinical trials for Coronavirus Vaccine no be di only one wey don see suspension
As tori of suspension of AstraZeneca / Oxford University vaccine trials reach pipo, make we look to oda Covid-19 vaccine trials like am wey no complete because one tin or di oda.
AstraZeneca and Oxford University bin suspend dia trial afta one participant get very serious reaction inside United Kingdom, although di drug company say di suspension na "routine" pause for di case of "one unexplained illness".
Dis dey come afta AstraZeneca and eight oda drug companies comot to say dem no go reduce di standard of dia Covid-19 drugs all in di name of say dem wan rush put am for market.
Gilead Sciences - April 2020
For April 2020, tori comot say American biopharmaceutical company Gilead Sciences go suspend di Covid-19 trials for China.
Di trial bin dey focus on how di antiviral remdesivir drug fit work for coronavirus patients wey dia cases dey serious or moderate.
According to di website clinicaltrialsarena.com Gilead Sciences say dia reason for di suspension na say China don dey already manage di outbreak for dia kontri, and so dem no fit find pesin wey go gree im body for di trial".
WHO - June 2020
Di World Health Organization cancel dia testing of di malaria drug hydroxychloroquine for trial treatment of Covid-19 patients.
Di trial wey dem bin dey conduct in different countries at di same time, march brake afta new studies torchlight say benefit no dey for patients wey dey take am.
WHO expert Ana Maria Henao-Restrepo investigators wey dey torchlight di drug - wey US President Donald Trump bin promote - look recent evidence and decide say dem go stop to recruit pipo for di trial.
Di British trial of "AstraZeneca" AZD1222 drug start for May with more than 12,000 participants, from 5 years old to over 70 and e don enta final stage for Brazil and South Africa.
Di U.S. trial, wey dey target 30,000 participants, launch last week as US goment bin don eye di drug to ready before di presidential election.
"Obviously, na challenge to dis particular vaccine trial," Britain Health Secretary Matt Hancock bin tell tori pipo on Tuesday.
Dis mata dey very important because AstraZeneca, don already agree to supply close to three billion doses to governments across di globe, including to Africa.
Di AstraZeneca-Oxford University vaccine na wetin pipo see as strong contender among dozens of odas wey dem dey develop world wide to tackle di Covid-19 pandemic.